<span item_type="fundamental" item_id="e72eb6ef95aaec04ddd5b8a7b71e2410" counter_id="ST/US/FBIOP" env="prod"></span><span item_type="announcement" item_id="516472062332962305" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 13.14 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.48.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -22.32 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Journey Medical Corporation</strong>: Net product revenue was $13.1 million for the three months ended March 31, 2025, compared to $13.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Loss from Operations</strong>: The consolidated loss from operations was $22.3 million for the three months ended March 31, 2025, compared to $36.6 million for the same period in 2024, reflecting a decrease of 39%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li><li><strong>Net Loss</strong>: The consolidated net loss was $24.7 million for the three months ended March 31, 2025, compared to $39.0 million for the same period in 2024, reflecting a decrease of 37%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: Net cash used in operating activities was $19.6 million for the three months ended March 31, 2025, compared to $25.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: Net cash provided by financing activities was $52.1 million for the three months ended March 31, 2025, compared to $27.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Stock-Based Compensation</strong>: Total stock-based compensation expense was $6.3 million for the three months ended March 31, 2025, compared to $4.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Fortress Biotech plans to continue developing its pipeline of product candidates by acquiring or in-licensing products, businesses, or technologies. The company aims to leverage its network to identify promising products and product candidates for potential acquisition.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into several partnerships and contingent sales of assets, including the planned acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries, Inc., which is subject to stockholder approval and other conditions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li><li><strong>Priority</strong>: The company emphasizes strategic collaborations and acquisitions to enhance its product pipeline and expand its market presence.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007898/fbio-20250331x10q.htm"></span></li></ul>

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q1 Revenue: USD 13.14 M